Flu Vaccine Production and Profits to Increase Through 2024

MarketsInsider - DPI Research, a global market research firm, released a recent report on flu vaccine production, coverage, and manufacturing profits through 2024. Following the 2017-2018 flu season where nearly 160 million vaccines were distributed, DPI predicts more than 185 million vaccinations by 2024 with pharmaceutical companies GlaxoSmithKline and Sanofi Pasteur increasing their sales profits well beyond the $1 billion mark.

The report focuses on new flu vaccine clinical trials from BiondVax, increased disease awareness and vaccination coverage, healthcare availability, and lower prices for medical providers in the United States and beyond. The forecast focuses on the following types of influenza vaccinations:

  • Fluzone High-Dose
  • Fluzone Quadrivalent
  • Intradermal (ID) Trivalent
  • Vaxigrip
  • Fluarix Quadrivalent
  • Flulaval Quadrivalent
  • Flucelvax Quadrivalent
  • Afluria Quadrivalent
  • Agrippal
  • Fluad
  • Fluvirin
  • Fluvax

As the upcoming 2018-2019 flu season quickly approaches, it is important to speak with your doctor if you or your child requires a flu vaccination. The Centers for Disease Control and Prevention (“CDC”) recommends that everyone over the ages of six (6) months should receive the seasonal influenza vaccine. According to the CDC, getting the flu vaccine is the best way to protect yourself against the flu and to help prevent its spread throughout the community. To learn more about the flu shot, prevention, and adverse reactions, check out our influenza page.